SCHEMBL5830675

SCHEMBL5830675

O=S(=O)(Nc1nc(-c2c(F)cccc2Cl)ns1)c1cc(Cl)c(Cl)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 1/20 0.41
ACLY P53396 2/20 0.38
CCR4 P51679 2/20 0.37
FSCN1 Q16658 1/20 0.37
IKBKB O14920 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
CRHBP P24387 1/20 0.34
HTT P42858 1/20 0.34
CRHR2 Q13324 1/20 0.34
CCR2 P41597 2/20 0.34
CCR1 P32246 1/20 0.34
KIT P10721 1/20 0.34
KDM1A O60341 5/20 0.33
PTGER3 P43115 2/20 0.33
MAOA P21397 2/20 0.33
LGALS8 O00214 1/20 0.33
LGALS3 P17931 1/20 0.33
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830884 0.83 PTGES2 (0.48) PTGES2ACLYCCR4IKBKBMEN1
SCHEMBL2763194 0.81 KDM1A (0.47) PTGES2MEN1KMT2AKDM1AMAOA
SCHEMBL5831877 0.81 PTGES2 (0.44) PTGES2ACLYCCR4FSCN1MEN1
SCHEMBL5831454 0.80 PFKFB3 (0.45) ACLYFSCN1LMNAHTTKDM1A
SCHEMBL27603911 0.79 HSD11B1 (0.35) ACLYFSCN1LMNAKDM1AMAOA
SCHEMBL5831684 0.76 RXFP1 (0.39) ACLYFSCN1KDM1AMAOA
SCHEMBL6613209 0.76 PTGES2 (0.48) PTGES2ACLYCCR4CCR2CCR1
SCHEMBL5830985 0.75 AKT1 (0.40)
SCHEMBL6612314 0.73 PTGES2 (0.48) PTGES2ACLYCCR4CCR2CCR1
SCHEMBL5396701 0.71 CCR4 (0.44) PTGES2ACLYCCR4IKBKBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 PTGES2 1107/4885ACLY 768/4885CCR4 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.